In this issue we include summaries of recent research papers on two of the therapies that may be used to treat TSC-related drug resistant epilepsy.
Many children are affected by drug-resistant epilepsy (DRE). Drug-resistant epilepsy can cause increased mortality, cognitive impairment/developmental delays and poorer quality of life. It is therefore important to control seizures to reduce developmental delays in paediatric epilepsy. Seizure control may be … Read More
Approximately 75% – 90% of individuals with TSC will have epilepsy at some point in their lives. There is renewed interest in the therapeutic benefits of cannabis medications, especially for individuals affected by treatment-resistant epilepsy, however clear prescribing guidelines for … Read More
Nearly 90% of individuals affected by TSC experience a wide range of neuropsychiatric symptoms that fall under the umbrella of TAND, TSC Associated Neuropsychiatric Disorders. These include behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial issues. Autism spectrum disorder (ASD) is … Read More
Some time ago Tuberous Sclerosis Australia (TSA) and Mito Foundation came together to support research examining costs incurred by families in Australia with children living with chronic and complex diseases. 13 families – 10 with TSC – generously gave their … Read More